FGK Clinical Research
FGK Clinical Research is recorded as a service provider in 22 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 22 trials · Latest update first
Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prevention of oesophageal strictures in adult patients after endoscopic submucosal dissection
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors
Sponsor Larkspur Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Single-arm, dose-escalation, Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter with a multiple-arm expansion group
Sponsor TME Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)
Sponsor Reata Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Enrollment was concentrated in the United States (131/172 participants), with 21 participants enrolled in the EEA: Austria 14 and Italy 7.
- The Part 2 primary mFARS analysis set excluded participants with pes cavus and included Week 48 data from 34 omaveloxolone-treated and 41 placebo-treated participants.
These findings describe the trial, not the service provider’s performance or responsibility.
P2-IMU-838-PMS - Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis (Calliper)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A first-in-human (FIH) clinical trial to investigate the human monoclonal antibody NG004, administrated intrathecally in acute spinal cord injury (SCI) patients
Sponsor NovaGo Therapeutics AG
- Start (EU)
- Latest update
- Estimated end
A Pivotal, Randomized, Placebo-Controlled, Double-Blind, Multicenter, International Phase III Clinical Trial to Investigate the Efficacy and Safety of allo-APZ2-CVU on Wound Healing of Therapy-Resistant Non-Healing Chronic Venous Ulcers (CVU)
Sponsor Rheacell GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
Sponsor Bonsai Biotherapeutics AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR)
Sponsor Sparrow Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)
Sponsor Immunic AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Placebo-Controlled, Double-blind, Dose-Ranging, Multicenter, Phase IIb Clinical Trial to Investigate the Efficacy and Safety of allo-APZ2-CVU on Wound Healing of Therapy-Resistant Chronic Venous Ulcer (CVU)
Sponsor Rheacell GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma – The GENESIS Study
Sponsor Bioline Rx Ltd.
- Start (EU)
- Latest update
- Estimated end
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Efficacy of Vitex agnus-castus BNO 1095 (20 mg) in women with primary dysmenorrhea
Sponsor Bionorica SE
- Start (EU)
- Latest update
- Estimated end
- Not reported
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-care in living donor kidney transplantation
Sponsor TolerogenixX GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults with Tourette Syndrome
Sponsor Neurothera Labs Inc.
- Start (EU)
- Latest update
- Estimated end
Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery.
Sponsor AM-Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for FGK Clinical Research?
The 2026-10-09 snapshot links FGK Clinical Research to 22 distinct CTIS trials. Recorded services include Medical writing, Regulatory services, Clinical monitoring, Safety reporting & pharmacovigilance, among 15 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for FGK Clinical Research?
The most frequently recorded therapeutic areas are Neurology, Immunology, Solid Tumor Oncology, Gastroenterology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to FGK Clinical Research conducted?
The linked trials record locations in 19 countries, including Germany, Poland, Austria, Sweden, Czechia. These are trial locations, not confirmed office locations or countries where FGK Clinical Research delivered services.
What can this page tell me about FGK Clinical Research's trial experience?
Browse 22 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under FGK Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- FGK Clinical Research GmbH